ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.59 CNY | +5.15% |
|
+5.85% | -31.89% |
| May. 29 | Starry Pharma Gets China Nod for MRI Contrast Agent Injectable | MT |
| May. 28 | Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it has received CNY 934.979955 million in funding | CI |
ETFs positioned on Zhejiang Starry Pharmaceutical Co.,Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +6.20% | - |
Zhejiang Starry Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of pharmaceutical specialty raw materials. The Company's business includes the production and sales of intermediates, APIs and preparations of iodine contrast agent series products such as iohexol, iopamidol, iodixanol, iomeprol, ioversol and iopromide. The Company's main products are non-ionic iodine contrast agent series drugs, levofloxacin series products, levofloxacin APIs and intermediates.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
9.59
CNY
Average target price
17.54
CNY
Spread / Average Target
+82.90%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.89% | 550M | |
| +60.25% | 846B | |
| +38.56% | 628B | |
| -4.49% | 360B | |
| +18.30% | 322B | |
| +9.64% | 297B | |
| +14.15% | 240B | |
| +3.11% | 224B | |
| +16.98% | 223B | |
| +12.87% | 173B |
- Stock Market
- Equities
- 603520 Stock
- ETFs Zhejiang Starry Pharmaceutical Co.,Ltd.
